Extraterrestrial Hemorrhage Control: Terrestrial Developments in Technique, Technology, and Philosophy with Applicability to Traumatic Hemorrhage in SpaceManaging injury and illness during long duration space flight limits efforts to explore beyond low earths orbit. Traumatic injury may be expected to occur in space and is a frequent cause of preventable deaths, often related to uncontrolled or ongoing hemorrhage (H). Such bleeding causes 40% of terrestrial injury mortality. Current guidelines emphasize early control of H compared to intravenous infusions. Recent advances in surgical and critical care may be applicable to trauma care in space, with appropriate considerations of the extreme logistical and personnel limitations. Methods: Recent developments in technique, resuscitation fluids, hemoglobin (Hb) substitutes, hemostatic agents, interventional angiography, damage control principles, and concepts related to suspended animation were reviewed. Results: H associated with instability frequently requires definitive intervention. Direct pressure should be applied to all compressible bleeding, but novel approaches are required for intracavitary noncompressible bleeding. Intravenous hemostatic agents such as recombinant Factor VII may facilitate hemostasis especially when combined with a controlled hypotension approach. Both open and laparoscopic techniques could be used in weightlessness, but require technical expertise not likely to be available. Specific rehearsed invasive techniques such as laparotomy with packing, or arterial catherterization with with robotic intravascular embolization might be considered . Hemodynamic support, thermal manipulation, or pharmacologic induction of a state of metabolic down regulation for whole body preservation may be appropriate. Hypertonic saline, with or without dextran, may temporize vascular support and decrease reperfusion injury, with less mass than other solutions. Hb substitutes have other theoretical advantages. Conclusions: Terrestrial developments suggest potential novel strategies to control H in space, but will required a coordinated program of evaluation and training to evaluate.
Document ID
20110011168
Acquisition Source
Johnson Space Center
Document Type
Abstract
Authors
Kirkpatrick, Andrew (Calgary Univ. Alberta, Canada)
Dawson, David (California Univ. Davis, CA, United States)
Campbell, Mark (Wyle Life Sciences, Inc. Paris, TX, United States)
Jones, Jeff (NASA Johnson Space Center Houston, TX, United States)
Ball, Chad G. (Calgary Univ. Alberta, Canada)
Hamilton, Douglas R. (Wyle Life Sciences, Inc. Houston, TX, United States)
Dulchavsky, Scott (Henry Ford Hospital Detroit, MI, United States)
McBeth, Paul (Calgary Univ. Alberta, Canada)
Holcomb, John (Army Inst. of Surgical Research Fort Sam Houston, TX, United States)
Date Acquired
August 25, 2013
Publication Date
May 2, 2004
Subject Category
Aerospace Medicine
Report/Patent Number
JSC-CN-8448Report Number: JSC-CN-8448
Meeting Information
Meeting: 75th AsMA Annual Scientific Meeting: Frontiers in Aerospace Medicine
Location: Anchorage, AK
Country: United States
Start Date: May 2, 2004
End Date: May 6, 2004
Sponsors: Aerospace Medicine Association Convention